China’s blood product makers face potentially challenging year
By Cornelia Zou
Wednesday, December 18, 2013
HONG KONG – The market for expensive blood products in China is attracting biotech companies looking to boost their bottom lines, but a surge in imports, driven by high supply levels abroad, is pressuring the bottom lines of domestic suppliers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.